Inhibitors of platelet activation and recruitment
OwnerCharles Richard Maliszewski, Richard Brownley Gayle III +2inventors
InventorsCharles Richard Maliszewski, Richard Brownley Gayle III, Virginia Lee Price, Steven Dean Gimpel
Life of this patent
Estimating the term…
Abstract
The present invention provides soluble CD39 polypeptides and compositions, and methods for inhibiting platelet activation and recruitment in a mammal comprising administering a soluble CD39 polypeptide.
Claims30
A polypeptide having the structure X-Y wherein X is selected from the group consisting of an Ala residue and heterologous peptides capable of adopting a stable secondary structure and Y is a soluble CD39 polypeptide selected from the group consisting of:
- (a) polypeptides having an amino acid sequence as set forth in FIG. 1 (SEQ ID NO:2) wherein the amino terminus is selected from the group consisting of amino acids 36-44, and the carboxy terminus is selected from the group consisting of amino acids 471-478;
- (b) fragments of the polypeptides of (a) wherein said fragments have apyrase activity;
- and
- (c) variants of the polypeptides of (a) or (b), wherein said variants have apyrase activity.
A polypeptide having the structure A-B-Y wherein A is 0-20 amino acids from the amino terminal portion of mature IL-2, B is a linker of 0-15 amino acids, and Y is a soluble CD39 polypeptide selected from the group consisting of:
- (a) polypeptides having an amino acid sequence as set forth in FIG. 1 (SEQ ID NO:2) wherein the amino terminus is selected from the group consisting of amino acids 36-44, and the carboxy terminus is selected from the group consisting of amino acids 471-478;
- (b) fragments of the polypeptides of (a) wherein said fragments have apyrase activity;
- and
- (c) variants of the polypeptides of (a) or (b), wherein said variants have apyrase activity.
A soluble CD39 polypeptide comprising a sequence selected from the group consisting of:
- (a) SEQ ID NO:
- 6, amino acids 25-464 of SEQ ID NO:27, amino acids 25-474 of SEQ ID NO:28, amino acids 27-473 of SEQ ID NO:29, amino acids 21-476 of SEQ ID NO:3, amino acids 21-476 of SEQ ID NO:4, or amino acids 21-463 of SEQ ID NO:30;
- and
- (b) fusion polypeptides comprising the polypeptides of (a), wherein said fusion polypeptides have apyrase activity.
A method of inhibiting angiogenesis in a mammal in need of such treatment comprising administering a therapeutic amount of a soluble CD39 polypeptide.
Dependencies are inferred from the claim text.